Skip to main content
editorial
. 2017 Aug 29;6(4):253–263. doi: 10.1159/000479573

Table 3.

Possible reasons for the success of REFLECT trial

- Good trial design
 Weight-based dosing (12 vs. 8 mg)
 Noninferiority trial design
- Potent anticancer activity over sorafenib
- Acceptable toxicity
- Longer treatment duration due to better tolerability, especially less hand-foot-skin reaction (5.7 vs. 3.7 months)